Erratum: The effect of Donepezil treatment on cardiovascular mortality (Clinical Pharmacology and Therapeutics (2010) 88 (335-338) DOI: 10.1038/clpt.2010.98);The effect of donepezil treatment on cardiovascular mortality

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 335-338

  Sato, K ^a   Urbano, R R ^b,c   Yu, C ^c   Yamasaki, F ^d   Sato, T ^d   Jordan, J ^e   Robertson, D ^a   Diedrich, A ^a,f  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d KOCHI MEDICAL SCHOOL   (Japan)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DEMENTIA; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LIPID DISORDER; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MORTALITY; MULTIINFARCT DEMENTIA; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; SURVIVAL RATE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED DEMENTIA; URINARY TRACT INFECTION; VOLUME DEPLETION;

EID: 77955917576     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.202     Document Type: Erratum

References (28)

1. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P. & Whalen, E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57, 613-620 (2001).
2. Black, S. et al. Efcacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 34, 2323-2330 (2003).
3. Kistler, P.M. et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J. Am. Coll. Cardiol. 44, 109-116 (2004).
4. Jones, S.A., Boyett, M.R. & Lancaster, M.K. Declining into failure: the age-dependent loss of the L-type calcium channel within the sinoatrial node. Circulation 115, 1183-1190 (2007).
5. Jones, S.A., Lancaster, M.K. & Boyett, M.R. Ageing-related changes of connexins and conduction within the sinoatrial node. J. Physiol. (Lond.) 560, 429-437 (2004).
6. La Rovere, M.T. et al. Barorefex sensitivity and heart rate variability in the identifcation of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 103, 2072-2077 (2001).
7. Lechat, P. et al. Heart rate and cardiac rhythm relationships with bisoprolol beneft in chronic heart failure in CIBIs II trial. Circulation 103, 1428-1433 (2001).
8. Winblad, B. et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57, 489-495 (2001).
9. Moretti, R., Torre, P., Vilotti, C., Antonello, R.M. & Pizzolato, G. Rivastigmine and parkinson dementia complex. Expert Opin. Pharmacother. 8, 817-829 (2007).
10. Kosasa, T., Kuriya, Y., Matsui, K. & Yamanishi, Y. Inhibitory efects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. Eur. J. Pharmacol. 386, 7-13 (1999).
11. Lazartigues, E. et al. Pressor and bradycardic efects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur. J. Pharmacol. 361, 61-71 (1998).
12. Savci, V., Gürün, M.S., Cavun, S. & Ulus, I.H. Cardiovascular efects of centrally injected tetrahydroaminoacridine in conscious normotensive rats. Eur. J. Pharmacol. 346, 35-41 (1998).
13. Bordier, P. et al. Cardiovascular efects and risk of syncope related to donepezil in patients with Alzheimer's disease. CNS Drugs 20, 411-417 (2006).
14. McLaren, A.T., Allen, J., Murray, A., Ballard, C.G. & Kenny, R.A. Cardiovascular efects of donepezil in patients with dementia. Dement. Geriatr. Cogn. Disord. 15, 183-188 (2003).
15. Masuda, Y. & Kawamura, A. Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. J. Cardiovasc. Pharmacol. 41 (suppl 1), s67-s71 (2003).
16. Aharon-peretz, J., Harel, T., Revach, M. & Ben-Haim, S.A. Increased sympathetic and decreased parasympathetic cardiac innervation in patients with Alzheimer's disease. Arch. Neurol. 49, 919-922 (1992).
17. Wang, S.J. et al. Cardiovascular autonomic functions in Alzheimer's disease. Age Ageing 23, 400-404 (1994).
18. Passmore, A.P., Bayer, A.J. & Steinhagen-thiessen, E. Cognitive, global, and functional benefts of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. J. Neurol. Sci. 229-230, 141-146 (2005).
19. Black, S.E. et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69, 459-469 (2007).
20. Wallin, A.K., Gustafson, L., Sjögren, M., Wattmo, C. & Minthon, L. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement. Geriatr. Cogn. Disord. 18, 197-206 (2004).
21. Li, M., Zheng, C., Sato, T., Kawada, T., Sugimachi, M. & Sunagawa, K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109, 120-124 (2004).
22. Kakinuma, Y. et al. Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1α. FEBS Lett. 579, 2111-2118 (2005).
23. Ando, M. et al. Eferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein. Circulation 112, 164-170 (2005).
24. Borroni, B. et al. Cholinesterase inhibitors exert a protective efect on endothelial damage in Alzheimer disease patients. J. Neurol. Sci. 229-230, 211-213 (2005).
25. Kakinuma, Y., Akiyama, T. & Sato, T. Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplifcation mechanism for vagal eferent efects in sparsely innervated ventricular myocardium. FEBS J. 276, 5111-5125 (2009).
26. Ott, B.R. & Lapane, K.L. tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J. Am. Geriatr. Soc. 50, 35-40 (2002).
27. Gasper, M.C., Ott, B.R. & Lapane, K.L. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am. J. Geriatr. Pharmacother. 3, 1-7 (2005).
28. López-pousa, S. et al. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Ageing 35, 365-371 (2006). (Pubitemid 43941803)